Novartis signs up-to-$3.2B subcutaneous delivery pact with Alteogen
Novartis signed an option and license agreement with Korean biotech Alteogen to use the ALT-B4 subcutaneous delivery technology, with potential value above $3.2 billion if milestones are met and exclusive rights are secured; upfront payment details weren’t disclosed. The deal adds to Alteogen’s growing roster of high‑profile clients (following deals with Biogen and GSK, among others) and reflects ongoing pharma interest in Alt-B4’s delivery tech, including past ties to Merck and AstraZeneca and Novartis’ 2024 exploration with Lindy Biosciences.